UroGen Pharma Ltd.
URGN- 1D
- -4.4%
UroGen Pharma Ltd. in brief
UroGen Pharma Ltd. is a listed company in the Biotechnology industry, based in New York, USA. It was founded in 2004. Its market value was $1.8 B on 15 October 2026, which makes it the 6,792nd largest listed company in the world and the 1,711th largest in the USA on this site. In the year to December 2025 it had sales of $110 M and a net loss of $153 M. Elizabeth A. Barrett is its chief executive. Its largest product and service lines by sales in 2025 were Jelmyto (86%) and Zusduri (14%). Its shares trade under the symbol URGN (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About UroGen Pharma Ltd.
UroGen Pharma is a Biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. The company annual revenue is 3.5 million USD and 156 employees as on 2020. The headquarters is in USA.
UroGen Pharma Ltd. timeline
- 2004
- 🏁· approximateFounded
- 2016
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 5 May 2017; shares registered for exchange trading on 1 May 2017.
- 2025
- 💰Record revenue of $110 millionFY2025, the highest of the 8 years on record.
Events of UroGen Pharma Ltd. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,218 (Jan 2020) · #2,942 (Jan 2021) · #3,852 (Jan 2022) · #3,739 (Dec 2022) · #2,637 (Jul 2023) · #2,655 (Jan 2024) · #865 (Mar 2026) · #1,557 (Aug 2026) · #1,665 (Oct 2026) · #1,712 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 16.3×
- Price / book
- —
- Free cash flow yield
- -9.1%
- Net margin
- -139.8%
- Operating margin
- -113.7%
- Return on equity
- —
- Liabilities / assets
- 152.6%
- Net debt
- $14M
- Revenue growth
- +21.4%
- R&D / revenue
- 61.1%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $110M | +21.4% | $-125M | $-153M | -139.8% |
| Dec 2024 | $90M | +9.3% | $-97M | $-127M | -140.3% |
| Dec 2023 | $83M | +28.5% | $-66M | $-102M | -123.6% |
| Dec 2022 | $64M | +34.0% | $-79M | $-110M | -170.6% |
| Dec 2021 | $48M | +307.1% | $-92M | $-111M | -230.7% |
| Dec 2020 | $12M | +58900.0% | $-127M | $-128M | -1088.8% |
| Dec 2019 | $0M | -98.2% | $-109M | $-105M | -525750.0% |
| Dec 2018 | $1M | — | $-77M | $-76M | -6695.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-162M | $0M | $-163M | — | — |
| Dec 2024 | $-97M | $0M | $-97M | — | — |
| Dec 2023 | $-76M | $0M | $-77M | — | — |
| Dec 2022 | $-88M | $0M | $-88M | — | — |
| Dec 2021 | $-85M | $1M | $-86M | $-4.96 | — |
| Dec 2020 | $-106M | $1M | $-107M | $-5.90 | — |
| Dec 2019 | $-71M | $0M | $-71M | $-5.12 | — |
| Dec 2018 | $-37M | $1M | $-38M | $-4.80 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $89M (+223.9% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report.
SEC filings
- Nov 4, 202610-QQuarterly report · period to Sep 2026
- Nov 4, 20268-KCurrent reportResults of operations
- Aug 20, 20268-KCurrent reportOther events
- Aug 5, 202610-QQuarterly report · period to Jun 2026
- Aug 5, 20268-KCurrent reportResults of operations
- Jun 23, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Jun 2, 20268-KCurrent reportOther events
- May 6, 202610-QQuarterly report · period to Mar 2026
- May 6, 20268-KCurrent reportResults of operations
- Apr 30, 2026DEF 14AProxy statement
- Mar 2, 202610-KAnnual report · period to Dec 2025
- Mar 2, 20268-KCurrent reportResults of operations
Official filings of UroGen Pharma Ltd. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $110 M
- Operating income
- $-125 M
- Net income
- $-153 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $200 M
- Total liabilities
- $306 M
- Total equity
- $-105 M
As of December-2025
Top 100 institutional investors in UroGen Pharma Ltd.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | RTW Investments, LP | 4,543,895 | 0 (0.00%) | 9.26% | $185 M | Nov 16, 2026 |
| 2 | BlackRock, Inc. | 3,108,202 | -93,259 (-2.91%) | 6.34% | $126 M | Nov 13, 2026 |
| 3 | Kynam Capital Management, LP | 2,434,207 | 0 (0.00%) | 4.96% | $99 M | Nov 16, 2026 |
| 4 | Jefferies Financial Group Inc. | 2,199,652 | 0 (0.00%) | 4.48% | $89 M | Nov 5, 2026 |
| 5 | Morgan Stanley | 2,174,808 | -401,555 (-15.59%) | 4.43% | $88 M | Nov 13, 2026 |
| 6 | Acorn Capital Advisors, LLC | 1,648,420 | -25,000 (-1.49%) | 3.36% | $67 M | Nov 16, 2026 |
| 7 | Opaleye Management Inc. | 1,439,996 | 0 (0.00%) | 2.94% | $59 M | Nov 16, 2026 |
| 8 | American Century Companies Inc | 1,375,304 | -310,415 (-18.41%) | 2.80% | $56 M | Nov 12, 2026 |
| 9 | D. E. Shaw & Co., Inc. | 1,283,889 | +138,070 (+12.05%) | 2.62% | $52 M | Nov 16, 2026 |
| 10 | Silverarc Capital Management, LLC | 1,148,689 | -153,290 (-11.77%) | 2.34% | $47 M | Nov 12, 2026 |
| 11 | Orbimed Advisors LLC | 988,487 | +312,300 (+46.19%) | 2.02% | $40 M | Nov 16, 2026 |
| 12 | State Street Corp | 975,787 | -27,284 (-2.72%) | 1.99% | $40 M | Nov 12, 2026 |
| 13 | Frontier Capital Management Co LLC | 936,144 | -572,403 (-37.94%) | 1.91% | $38 M | Nov 16, 2026 |
| 14 | MPM Bioimpact LLC | 909,691 | -23,724 (-2.54%) | 1.85% | $37 M | Nov 16, 2026 |
| 15 | Goldman Sachs Group Inc | 848,342 | +28,508 (+3.48%) | 1.73% | $34 M | Nov 16, 2026 |
| 16 | Migdal Insurance & Financial Holdings Ltd. | 770,909 | 0 (0.00%) | 1.57% | $31 M | Nov 9, 2026 |
| 17 | Parkman Healthcare Partners LLC | 750,202 | +576,138 (+330.99%) | 1.53% | $30 M | Nov 16, 2026 |
| 18 | Geode Capital Management, LLC | 617,513 | +7,149 (+1.17%) | 1.26% | $25 M | Nov 6, 2026 |
| 19 | Woodline Partners LP | 500,726 | 0 (0.00%) | 1.02% | $20 M | Nov 16, 2026 |
| 20 | Boxer Capital Management, LLC | 500,000 | 0 (0.00%) | 1.02% | $20 M | Nov 16, 2026 |
| 21 | Elmind Capital, LP | 491,100 | +371,100 (+309.25%) | 1.00% | $20 M | Nov 16, 2026 |
| 22 | Vanguard Portfolio Management LLC | 462,075 | +5,517 (+1.21%) | 0.94% | $19 M | Nov 13, 2026 |
| 23 | Two Sigma Investments, LP | 406,299 | +257,336 (+172.75%) | 0.83% | $17 M | Nov 16, 2026 |
| 24 | ADAR1 Capital Management, LLC | 369,785 | +117,390 (+46.51%) | 0.75% | $15 M | Nov 16, 2026 |
| 25 | Nomura Asset Management International Inc. | 366,973 | New | 0.75% | $15 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Walleye Capital LLC | 348,116 | New | 0.71% | $14 M | Nov 13, 2026 |
| 27 | Hennion & Walsh Asset Management, Inc. | 309,584 | +32,888 (+11.89%) | 0.63% | $13 M | Oct 13, 2026 |
| 28 | Federated Hermes, Inc. | 305,217 | +304,259 (+31759.81%) | 0.62% | $12 M | Nov 12, 2026 |
| 29 | Northern Trust Corp | 303,188 | -1,382 (-0.45%) | 0.62% | $12 M | Nov 16, 2026 |
| 30 | Next Century Growth Investors LLC | 297,083 | New | 0.61% | $12 M | Nov 13, 2026 |
| 31 | Schonfeld Strategic Advisors LLC | 295,809 | +263,350 (+811.33%) | 0.60% | $12 M | Nov 16, 2026 |
| 32 | Oberweis Asset Management Inc/ | 295,625 | New | 0.60% | $12 M | Nov 16, 2026 |
| 33 | Qube Research & Technologies Ltd | 287,222 | New | 0.59% | $12 M | Nov 13, 2026 |
| 34 | AQR Capital Management LLC | 283,615 | +134,387 (+90.05%) | 0.58% | $12 M | Nov 16, 2026 |
| 35 | Millennium Management LLC | 268,902 | +162,210 (+152.04%) | 0.55% | $11 M | Nov 16, 2026 |
| 36 | UBS Group AG | 266,218 | +144,757 (+119.18%) | 0.54% | $11 M | Nov 10, 2026 |
| 37 | Nuveen, LLC | 240,822 | +148,720 (+161.47%) | 0.49% | $10 M | Nov 10, 2026 |
| 38 | Bank Of America Corp /de/ | 235,848 | -239,854 (-50.42%) | 0.48% | $10 M | Nov 16, 2026 |
| 39 | FMR LLC | 230,871 | +33,773 (+17.14%) | 0.47% | $9 M | Nov 10, 2026 |
| 40 | Soleus Capital Management, L.P. | 230,274 | -599,536 (-72.25%) | 0.47% | $9 M | Nov 16, 2026 |
| 41 | Rice Hall James & Associates, LLC | 226,046 | -74,604 (-24.81%) | 0.46% | $9 M | Nov 16, 2026 |
| 42 | Jpmorgan Chase & Co | 210,356 | +170,812 (+431.95%) | 0.43% | $9 M | Nov 12, 2026 |
| 43 | Superstring Capital Management LP | 184,392 | -6,921 (-3.62%) | 0.38% | $7 M | Nov 16, 2026 |
| 44 | Russell Investments Group, Ltd. | 183,076 | +88,097 (+92.75%) | 0.37% | $7 M | Nov 6, 2026 |
| 45 | ING Groep NV | 180,000 | New | 0.37% | $7 M | Nov 10, 2026 |
| 46 | Wellington Management Group LLP | 168,792 | +53,430 (+46.32%) | 0.34% | $7 M | Nov 16, 2026 |
| 47 | J. Goldman & Co LP | 149,139 | -63,636 (-29.91%) | 0.30% | $6 M | Nov 16, 2026 |
| 48 | Charles Schwab Investment Management Inc | 128,297 | -73 (-0.06%) | 0.26% | $5 M | Nov 16, 2026 |
| 49 | Squarepoint Ops LLC | 117,199 | +105,500 (+901.79%) | 0.24% | $5 M | Nov 9, 2026 |
| 50 | Tidal Investments LLC | 112,990 | +11,153 (+10.95%) | 0.23% | $5 M | Nov 13, 2026 |
| 51 | Neo Ivy Capital Management | 111,430 | New | 0.23% | $5 M | Nov 13, 2026 |
| 52 | Aisling Capital Management LP | 108,000 | 0 (0.00%) | 0.22% | $4 M | Nov 12, 2026 |
| 53 | Privium Fund Management B.V. | 107,915 | -102,085 (-48.61%) | 0.22% | $4 M | Nov 3, 2026 |
| 54 | Susquehanna International Group, LLP | 106,837 | +100,055 (+1475.30%) | 0.22% | $4 M | Nov 16, 2026 |
| 55 | Informed Momentum Co LLC | 106,013 | +26,742 (+33.73%) | 0.22% | $4 M | Nov 16, 2026 |
| 56 | Atom Investors LP | 104,599 | +57,935 (+124.15%) | 0.21% | $4 M | Nov 16, 2026 |
| 57 | Bank of New York Mellon Corp | 102,516 | -10,512 (-9.30%) | 0.21% | $4 M | Nov 5, 2026 |
| 58 | Arrowstreet Capital, Limited Partnership | 89,885 | New | 0.18% | $4 M | Nov 13, 2026 |
| 59 | Swiss National Bank | 78,800 | +1,000 (+1.29%) | 0.16% | $3 M | Nov 12, 2026 |
| 60 | BNP Paribas Financial Markets | 77,648 | +34,049 (+78.10%) | 0.16% | $3 M | Nov 12, 2026 |
| 61 | Oak Ridge Investments LLC | 74,743 | -13,848 (-15.63%) | 0.15% | $3 M | Oct 30, 2026 |
| 62 | State Of Wisconsin Investment Board | 74,403 | +39,349 (+112.25%) | 0.15% | $3 M | Nov 16, 2026 |
| 63 | XTX Topco Ltd | 72,388 | +53,002 (+273.40%) | 0.15% | $3 M | Nov 16, 2026 |
| 64 | Truist Financial Corp | 72,303 | +17 (+0.02%) | 0.15% | $3 M | Oct 30, 2026 |
| 65 | Panagora Asset Management Inc | 67,456 | -6,568 (-8.87%) | 0.14% | $3 M | Nov 12, 2026 |
| 66 | Jump Financial, LLC | 65,100 | New | 0.13% | $3 M | Nov 13, 2026 |
| 67 | Raymond James Financial Inc | 60,148 | New | 0.12% | $2 M | Nov 12, 2026 |
| 68 | Jacobs Levy Equity Management, Inc | 55,667 | +34,971 (+168.97%) | 0.11% | $2 M | Nov 16, 2026 |
| 69 | ARK Investment Management LLC | 54,250 | -47,258 (-46.56%) | 0.11% | $2 M | Nov 13, 2026 |
| 70 | Rhumbline Advisers | 53,588 | -1,334 (-2.43%) | 0.11% | $2 M | Nov 10, 2026 |
| 71 | Wells Fargo & Company/mn | 49,901 | -30,333 (-37.81%) | 0.10% | $2 M | Nov 16, 2026 |
| 72 | Deutsche Bank AG\ | 47,292 | -4,258 (-8.26%) | 0.10% | $2 M | Nov 6, 2026 |
| 73 | Polen Capital Management LLC | 46,801 | +17,186 (+58.03%) | 0.10% | $2 M | Nov 13, 2026 |
| 74 | Voya Investment Management LLC | 46,629 | -24,631 (-34.56%) | 0.10% | $2 M | Nov 10, 2026 |
| 75 | California State Teachers Retirement System | 44,949 | 0 (0.00%) | 0.09% | $2 M | Nov 13, 2026 |
| 76 | ExodusPoint Capital Management, LP | 44,645 | New | 0.09% | $2 M | Nov 16, 2026 |
| 77 | Alliancebernstein L.P. | 43,710 | 0 (0.00%) | 0.09% | $2 M | Nov 16, 2026 |
| 78 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 42,767 | +41,893 (+4793.25%) | 0.09% | $2 M | Nov 16, 2026 |
| 79 | Royal Bank Of Canada | 38,930 | +27,870 (+251.99%) | 0.08% | $2 M | Nov 16, 2026 |
| 80 | Coastal Bridge Advisors, LLC | 38,250 | +1,250 (+3.38%) | 0.08% | $2 M | Nov 18, 2026 |
| 81 | Cetera Investment Advisers | 37,422 | +8,470 (+29.26%) | 0.08% | $2 M | Nov 13, 2026 |
| 82 | Vanguard Fiduciary Trust Co | 36,275 | -932 (-2.50%) | 0.07% | $1 M | Nov 13, 2026 |
| 83 | Legal & General Group Plc | 35,830 | 0 (0.00%) | 0.07% | $1 M | Nov 16, 2026 |
| 84 | Citadel Advisors LLC | 35,665 | +22,680 (+174.66%) | 0.07% | $1 M | Nov 16, 2026 |
| 85 | Price T Rowe Associates Inc /MD/ | 35,343 | +340 (+0.97%) | 0.07% | $1 M | Nov 16, 2026 |
| 86 | Prudential Financial Inc | 34,738 | +27,763 (+398.04%) | 0.07% | $1 M | Nov 16, 2026 |
| 87 | Bender Robert & Associates | 34,701 | New | 0.07% | $1 M | Oct 21, 2026 |
| 88 | Focus Partners Wealth | 33,434 | +373 (+1.13%) | 0.07% | $1 M | Nov 12, 2026 |
| 89 | Engineers Gate Manager LP | 33,278 | +16,900 (+103.19%) | 0.07% | $1 M | Nov 16, 2026 |
| 90 | Barclays PLC | 31,294 | +21,119 (+207.56%) | 0.06% | $1 M | Nov 6, 2026 |
| 91 | Algert Global LLC | 31,120 | -1,230 (-3.80%) | 0.06% | $1 M | Nov 17, 2026 |
| 92 | Gilder Gagnon Howe & Co LLC | 30,148 | New | 0.06% | $1 M | Nov 16, 2026 |
| 93 | VANGUARD ASSET MANAGEMENT, Ltd | 29,666 | +3,662 (+14.08%) | 0.06% | $1 M | Nov 13, 2026 |
| 94 | Ameriprise Financial Inc | 29,181 | -2,487 (-7.85%) | 0.06% | $1 M | Nov 16, 2026 |
| 95 | Jain Global LLC | 26,014 | +19,112 (+276.91%) | 0.05% | $1 M | Nov 16, 2026 |
| 96 | Invesco Ltd. | 24,868 | -1,059 (-4.08%) | 0.05% | $1 M | Nov 12, 2026 |
| 97 | MetLife Investment Management, LLC | 24,865 | 0 (0.00%) | 0.05% | $1 M | Nov 16, 2026 |
| 98 | Palo Alto Investors LP | 24,500 | 0 (0.00%) | 0.05% | $1 M | Nov 16, 2026 |
| 99 | Franklin Templeton Inc | 21,836 | +2,573 (+13.36%) | 0.04% | $1 M | Nov 12, 2026 |
| 100 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 20,347 | +811 (+4.15%) | 0.04% | $1 M | Nov 16, 2026 |
Superinvestors holding UroGen Pharma Ltd.
1 of the well-known investors value.today follows, from their newest Form 13F.
- Polen Capital · Polen Capital's team$2 M+17,186 · Sep 30, 2026
Mutual funds holding UroGen Pharma Ltd.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.11 M | $41 M | 2.3% | 0.05% | +13% | Jun 30, 2026 |
| 🇺🇸 Small Cap Growth FundAmerican Century Investment Management, Inc. | 874,981 | $33 M | 1.8% | 0.60% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 465,265 | $18 M | 0.95% | 0.05% | +17% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 339,426 | $12 M | 0.69% | 0.08% | +26% | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 290,394 | $11 M | 0.59% | 0.12% | +1.5% | Jun 30, 2026 |
| 🇺🇸 State Street SPDR Portfolio Developed World ex-US ETFSSGA Funds Management, Inc. | 184,678 | $7 M | 0.38% | 0.02% | −0.1% | Jun 30, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 175,588 | $6 M | 0.36% | 0.11% | +42% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 206,762 | $6 M | 0.42% | 0.03% | +13% | May 31, 2026 |
| 🇺🇸 Vanguard Explorer Value FundFrontier Capital Management Company, LLC | 189,986 | $5 M | 0.39% | 0.43% | +52% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 143,206 | $5 M | 0.29% | 0.35% | +41% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 103,478 | $4 M | 0.21% | 0.05% | +17% | Jul 31, 2026 |
| 🇺🇸 Calamos Timpani Small Cap Growth FundCalamos Advisors LLC | 97,953 | $4 M | 0.20% | 0.49% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 118,284 | $3 M | 0.24% | 0.02% | +0.1% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 79,645 | $3 M | 0.16% | 0.05% | +28% | Jun 30, 2026 |
| 🇺🇸 Small Cap Growth FundThe Variable Annuity Life Insurance Company | 94,936 | $3 M | 0.19% | 0.49% | −5.9% | May 31, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC | 89,168 | $3 M | 0.18% | 0.05% | −1.2% | May 29, 2026 |
| 🇺🇸 Clearwater Select Equity FundClearwater Management Co Inc. | 67,706 | $2 M | 0.14% | 0.48% | +10% | Jun 30, 2026 |
| 🇺🇸 Federated Hermes MDT Small Cap Growth FundFederated Hermes MDT Series | 60,521 | $2 M | 0.12% | 0.28% | new | Jul 31, 2026 |
| 🇺🇸 ARK Israel Innovative Technology ETFARK Investment Management LLC | 54,250 | $2 M | 0.11% | 1.5% | −47% | Jul 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 52,750 | $2 M | 0.11% | 0.05% | +9.5% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 52,288 | $2 M | 0.11% | 0.01% | −16% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 46,239 | $2 M | 0.09% | 0.04% | +7.0% | Jun 30, 2026 |
| 🇺🇸 Tema Oncology ETFTema ETFs LLC | 58,518 | $2 M | 0.12% | 0.93% | −13% | May 31, 2026 |
| 🇺🇸 Amplify BlueStar Israel Technology ETFAmplify ETF Trust | 43,319 | $2 M | 0.09% | 1.3% | +44% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 37,512 | $1 M | 0.08% | 0.15% | +201% | Jul 31, 2026 |
| 🇺🇸 M Capital Appreciation FundNorthern Lights Fund Trust II | 36,861 | $1 M | 0.08% | 0.43% | — | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 34,807 | $1 M | 0.07% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 34,456 | $1 M | 0.07% | 0.08% | +37% | Jun 30, 2026 |
| 🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors | 30,659 | $1 M | 0.06% | 0.03% | new | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 30,200 | $1 M | 0.06% | 0.05% | +20% | Jun 30, 2026 |
| 🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc. | 25,821 | $1 M | 0.05% | 0.11% | +49% | Jun 30, 2026 |
| 🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc. | 33,104 | $1 M | 0.07% | 0.05% | −59% | May 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 25,250 | $1 M | 0.05% | 0.05% | +40% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Equity FundCharles Schwab Investment Management, Inc. | 23,370 | $1 M | 0.05% | 0.14% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 31,194 | $1 M | 0.06% | 0.05% | +13% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 30,686 | $1 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 21,528 | $1 M | 0.04% | 0.05% | +12% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 20,398 | $1 M | 0.04% | 0.05% | +17% | Jul 31, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 19,515 | $1 M | 0.04% | 0.11% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC | 18,561 | $1 M | 0.04% | 0.02% | +2.9% | Jul 31, 2026 |
| 🇺🇸 M Capital Appreciation FundM Financial Investment Advisers, Inc. | 37,221 | $1 M | 0.08% | 0.25% | — | Mar 31, 2026 |
| 🇺🇸 LVIP Franklin Templeton Multi-Factor SMID Cap Equity FundLincoln Financial Investments Corporation | 17,633 | $1 M | 0.04% | 0.06% | +5.8% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 21,882 | $1 M | 0.04% | 0.06% | +1.3% | May 31, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 15,036 | $1 M | 0.03% | <0.01% | +57% | Jun 30, 2026 |
| 🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC | 14,146 | $1 M | 0.03% | 0.21% | +163% | Jul 31, 2026 |
| 🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC | 14,273 | $1 M | 0.03% | 0.14% | +523% | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 14,200 | $1 M | 0.03% | 0.02% | +3.6% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 14,183 | $1 M | 0.03% | 0.05% | +23% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 14,096 | $1 M | 0.03% | 0.05% | +0.6% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 13,730 | $1 M | 0.03% | 0.02% | −1.4% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 12,566 | $0 M | 0.03% | <0.01% | +189% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 12,201 | $0 M | 0.02% | 0.05% | +15% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 15,749 | $0 M | 0.03% | 0.03% | +7.6% | May 31, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 11,210 | $0 M | 0.02% | 0.10% | −2.8% | Jun 30, 2026 |
| 🇺🇸 Column Small Cap FundTrust for Professional Managers | 14,607 | $0 M | 0.03% | 0.08% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC | 14,314 | $0 M | 0.03% | <0.01% | +1.6% | May 31, 2026 |
| 🇺🇸 Tax-Managed U.S. Mid & Small Cap FundRussell Investment Management, LLC | 9,452 | $0 M | 0.02% | 0.02% | no change | Jul 31, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 9,634 | $0 M | 0.02% | 0.01% | −43% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 9,556 | $0 M | 0.02% | 0.16% | +32% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 9,417 | $0 M | 0.02% | 0.05% | +19% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 8,547 | $0 M | 0.02% | 0.05% | +17% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 8,068 | $0 M | 0.02% | 0.01% | −7.5% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 6,726 | $0 M | 0.01% | 0.02% | +23% | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 6,694 | $0 M | 0.01% | 0.05% | +19% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 6,425 | $0 M | 0.01% | 0.05% | +36% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 6,291 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 5,736 | $0 M | 0.01% | 0.05% | +16% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 5,347 | $0 M | 0.01% | 0.04% | +18% | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 5,152 | $0 M | 0.01% | 0.05% | +19% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 5,128 | $0 M | 0.01% | 0.08% | +76% | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 4,797 | $0 M | <0.01% | 0.05% | +18% | Jul 31, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 5,900 | $0 M | 0.01% | 0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 5,556 | $0 M | 0.01% | 0.01% | +17% | May 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 3,759 | $0 M | <0.01% | 0.05% | +15% | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 3,867 | $0 M | <0.01% | 0.05% | +25% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 3,455 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 3,386 | $0 M | <0.01% | 0.05% | +18% | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 3,206 | $0 M | <0.01% | <0.01% | +55% | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 3,222 | $0 M | <0.01% | 0.08% | +31% | Jun 30, 2026 |
| 🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC | 6,541 | $0 M | 0.01% | 0.07% | — | Mar 31, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 3,016 | $0 M | <0.01% | <0.01% | +87% | Jul 31, 2026 |
| 🇺🇸 Avantis Total Equity Markets ETFAmerican Century ETF Trust | 3,775 | $0 M | <0.01% | 0.01% | no change | May 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 2,859 | $0 M | <0.01% | 0.05% | +15% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 3,496 | $0 M | <0.01% | <0.01% | +20% | May 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 1,845 | $0 M | <0.01% | <0.01% | −34% | Jun 30, 2026 |
| 🇺🇸 iShares MSCI World Small-Cap ETFBlackRock Fund Advisors | 2,395 | $0 M | <0.01% | 0.01% | new | May 31, 2026 |
| 🇺🇸 Strategic Allocation: Aggressive FundAmerican Century Strategic Asset Allocations Inc | 1,558 | $0 M | <0.01% | <0.01% | −5.4% | Jul 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,488 | $0 M | <0.01% | 0.02% | +26% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 1,894 | $0 M | <0.01% | 0.03% | +19% | May 31, 2026 |
| 🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC | 1,433 | $0 M | <0.01% | 0.04% | −64% | Jun 30, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 1,500 | $0 M | <0.01% | 0.01% | −34% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 1,481 | $0 M | <0.01% | 0.02% | −35% | May 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,076 | $0 M | <0.01% | <0.01% | +26% | Jun 30, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 1,318 | $0 M | <0.01% | <0.01% | −5.0% | May 31, 2026 |
| 🇺🇸 Strategic Allocation: Moderate FundAmerican Century Strategic Asset Allocations Inc | 967 | $0 M | <0.01% | <0.01% | −28% | Jul 31, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 936 | $0 M | <0.01% | <0.01% | −18% | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 784 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 762 | $0 M | <0.01% | <0.01% | +2.4% | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 907 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC | 525 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at UroGen Pharma Ltd.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Chris DegnanChief Financial Officer | Option exercise | +4,483 | — | — | 6,763 | Form 4 |
| filed | Chris DegnanChief Financial Officer | Sell | -2,202 | $36.69 | $81 K | 4,561 | Form 4 |
| filed | Jason Drew SmithGeneral Counsel | Sell | -1,519 | $42.54 | $65 K | 53,141 | Form 4 |
| filed | Mark SchoenbergChief Medical Officer | Sell | -871 | $42.92 | $37 K | 59,882 | Form 4 |
| filed | Jason Drew SmithGeneral Counsel | Option exercise | +3,334 | — | — | 54,660 | Form 4 |
| filed | Mark SchoenbergChief Medical Officer | Option exercise | +1,667 | — | — | 60,753 | Form 4 |
| filed | James A. Robinson Jr.Director | Option exercise | +2,000 | — | — | 8,000 | Form 4 |
| filed | Mark SchoenbergChief Medical Officer | Sell | -60,677 | $47.05 | $2.9 M | 59,086 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: UroGen Pharma Ltd.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 3.2-for-1 split
Trading halts
- 2025-06-12 15:56 UTC, code T3, resumed 18:00 UTC
- 2025-05-21 10:55 UTC, code T3, resumed 16:55 UTC
Fails to deliver
- : 146,112 shares at $36.58
- : 185 shares at $38.26
- : 39,984 shares at $38.28
- : 200 shares at $40.70
- : 9,187 shares at $41.23
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
UroGen Pharma Ltd. scorecard#
Passes 6 of the 17 checks that could be worked out: strongest in growth (4 of 5), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 15, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✗Price to sales below its peers' median16.3×Price to sales 16.3× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-9.1%Free cash flow is -9.1% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 5
- ✓Revenue grew in the newest year21.4%Revenue up 21.4% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years19.5%19.5% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median19.5%19.5% a year against Biotechnology's median of 12.9% (181 companies).
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$153 M-$153 M in fiscal 2025 against -$128 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability1 of 4
- ✗Profitable in the newest year-$153 MNet income -$153 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-113.7%-113.7% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-113.7%-113.7% in fiscal 2025 against -122.8% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities4.0×Current ratio 4.01 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-3.86Z-score -3.86 (distress zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from UroGen Pharma Ltd.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -113.7% | -60.5% | |
| Net margin | -139.8% | -68.9% | |
| Revenue growth, 3 years a year | 19.5% | 12.9% | |
| Revenue growth | 21.5% | 15.8% | |
| Free cash flow margin | -148.2% | -61.5% |
1of 9on the Piotroski tests of financial strength
- Net loss of $153 million, the 11th loss-making year in a row.
- Free cash flow was negative: -$163 million.
- Shareholders' equity is negative: -$105 million.
- Receivables grew 63% while revenue grew 21%: customers are paying later, or sales were booked ahead of cash.
UroGen Pharma Ltd.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 110+21.4%100% | 90+9.3%100% | 83+28.5%100% | 64+34.0%100% | 48+307%100% | 12+65450%100% | 0.0−98.4%100% | 1.1−86.2%100% | 8.2−53.5%100% | 18—100% | |
| Cost of revenue | 12+40.2%11.3% | 8.9−5.1%9.8% | 9.4+22.3%11.3% | 7.7+48.4%11.9% | 5.2+411%10.7% | 1.0—8.6% | — | 1.8+201%160% | 0.6+2043%7.4% | 0.0—0.2% | |
| Gross profit | 97+19.4%88.7% | 82+11.1%90.2% | 73+29.4%88.7% | 57+32.2%88.1% | 43+297%89.3% | 11+59844%91.4% | 0.0—100% | −0.7−109%−59.8% | 7.6−56.8%92.6% | 18—99.8% | |
| Research and development | 67+17.4%61.1% | 57+25.3%63.2% | 46−13.8%55.1% | 53+11.0%82.2% | 48+0.7%99.2% | 47−4.0%401% | 49+33.5%273872% | 37+97.5%3274% | 19—229% | — | |
| Selling, general and administrative | 155+28.0%141% | 121+29.9%134% | 93+12.6%113% | 83−5.4%129% | 88−3.0%182% | 90+49.9%765% | 60—334439% | — | — | — | |
| General and administrative | — | — | — | — | — | — | 60+52.1%334439% | 40+349%3508% | 8.8+37.3%108% | 6.4—36.6% | |
| Operating expenses | — | — | — | — | — | — | 109+43.1%608311% | 77+178%6782% | 28—337% | — | |
| Operating income | −125—−114% | −97—−107% | −66—−79.2% | −79—−123% | −92—−192% | −127—−1074% | −109—−608211% | −77—−6842% | −20−2600%−245% | 0.8—4.6% | |
| Interest and finance income | 6.0−33.0%5.4% | 8.9+237%9.8% | 2.6+182%3.2% | 0.9+157%1.5% | 0.4−81.6%0.8% | 2.0−57.0%16.8% | 4.6—25644% | — | — | — | |
| Other non-operating income (expense) | −0.7—−0.6% | −0.2−127%−0.3% | 0.8+1064%1.0% | 0.1—0.1% | −0.2—−0.3% | — | −0.3—−1578% | −0.1−1133%−11.0% | 0.0—0.1% | — | |
| Income before tax | −153—−140% | −124—−137% | −98—−119% | −108—−168% | −109—−228% | −125—−1060% | −105—−584144% | −76—−6696% | −20—−245% | −1.9—−11.1% | |
| Income tax | 0.1−97.2%0.1% | 2.8−27.8%3.1% | 3.9+123%4.7% | 1.8+21.1%2.7% | 1.4−57.1%3.0% | 3.4—28.6% | — | 0.1+558%11.1% | 0.0—0.2% | — | |
| Net income attributable to shareholders | −153—−140% | −127—−140% | −102—−124% | −110—−171% | −111—−231% | −128—−1089% | −105—−584144% | −76—−6707% | −20—−245% | −1.9—−11.1% | |
| Earnings per share, basic | -3.19—— | -2.96—— | -3.55—— | -4.81—— | -4.96—— | -5.90—— | -5.12—— | -4.80—— | -2.14—— | -1.91—— | |
| Earnings per share, diluted | — | — | — | — | -4.96—— | -5.90—— | -5.12—— | -4.80—— | -2.14—— | -1.91—— | |
| Shares, weighted average (basic) | 48+12.2%— | 43+48.7%— | 29+26.4%— | 23+2.1%— | 22—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | — | — | — | — | 22+2.6%— | 22+6.1%— | 21+30.3%— | 16+62.1%— | 9.7+321%— | 2.3—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 111−35.6%55.2% | 172+81.0%60.2% | 95+71.5%53.3% | 55+24.9%40.9% | 44−16.1%37.0% | 53+6.4%43.3% | 50−51.0%24.6% | 101+174%97.8% | 37+73.2%49.0% | 21—92.7% | |
| Short-term investments | 49−55.4%24.6% | 111r111+97.1%38.7% | 56r56+26.0%31.5% | 45−0.5%32.9% | 45−8.9%37.4% | 49−49.5%40.3% | 97—48.1% | — | 36—47.7% | — | |
| Receivables | 33+62.9%16.5% | 20+31.5%7.1% | 15+21.6%8.7% | 13+8.4%9.4% | 12+66.3%9.8% | 7.0—5.8% | — | — | — | 0.1—0.4% | |
| Inventory | 16+78.4%8.2% | 9.2+62.6%3.2% | 5.7+31.2%3.2% | 4.3−10.5%3.2% | 4.8+146%4.0% | 2.0—1.6% | — | — | 0.3+201%0.4% | 0.1—0.5% | |
| Other current assets | 15+65.9%7.3% | 8.8−14.0%3.1% | 10−7.4%5.8% | 11+48.5%8.2% | 7.5+122%6.2% | 3.4+225%2.8% | 1.0+53.9%0.5% | 0.7−29.9%0.6% | 1.0+142%1.3% | 0.4—1.7% | |
| Current assets | 186−32.6%92.8% | 276+63.2%96.6% | 169+31.2%94.9% | 129+12.7%95.1% | 114−1.1%95.5% | 116−22.2%94.8% | 149+45.4%73.4% | 102+37.3%98.7% | 74+238%98.6% | 22—95.6% | |
| Property, plant and equipment | 0.6−2.7%0.3% | 0.7−4.9%0.2% | 0.7−46.9%0.4% | 1.3−34.1%1.0% | 2.0−3.9%1.6% | 2.0+109%1.7% | 1.0+3.1%0.5% | 0.9+17.8%0.9% | 0.8+8.6%1.1% | 0.7—3.2% | |
| Right-of-use (leased) assets | 3.1+263%1.5% | 0.8—0.3% | 0r1.7−100%0.0% | 2.5+108%1.8% | 1.2−45.3%1.0% | 2.2−42.2%1.8% | 3.7—1.8% | — | — | — | |
| Total assets | 200−29.8%100% | 286+60.2%100% | 178+31.5%100% | 136+13.3%100% | 120−1.9%100% | 122−39.7%100% | 202+95.4%100% | 104+37.1%100% | 76+228%100% | 23—100% | |
| Accounts payable | 12+11.0%6.1% | 11+67.8%3.8% | 6.5+17.9%3.7% | 5.5−4.5%4.1% | 5.8+76.9%4.8% | 3.3−30.3%2.7% | 4.7+9.9%2.3% | 4.3+50.5%4.1% | 2.8r4.4+51.0%3.8% | 1.9—8.2% | |
| Current liabilities | 46+1.0%23.2% | 46+47.2%16.1% | 31+30.5%17.5% | 24+6.9%17.6% | 22+4.4%18.7% | 21+10.0%17.6% | 19+44.7%9.6% | 13+91.4%13.0% | 7.0+124%9.3% | 3.1—13.6% | |
| Long-term debt | 122+0.4%61.0% | 122+23.5%42.6% | 99+1.0%55.3% | 98—71.9% | 0—0.0% | — | — | — | — | — | |
| Lease liabilities (non-current) | 2.6r2.6+4464%1.3% | 0.1—0.0% | 0r0.8−100%0.0% | 1.6+298%1.2% | 0.4−73.4%0.3% | 1.5−42.5%1.2% | 2.6—1.3% | — | — | — | |
| Total liabilities | 306+3.9%153% | 295+20.9%103% | 244+8.2%137% | 225+102%166% | 111+334%93.0% | 26+16.1%21.0% | 22+64.0%10.9% | 13+91.4%13.0% | 7.0+4.2%9.3% | 6.7—29.3% | |
| Retained earnings | −960—−479% | −806—−282% | −679—−381% | −577—−426% | −467—−390% | −357—−292% | −228—−113% | −123—−119% | −47—−62.5% | −27—−118% | |
| Shareholders' equity | −105—−52.6% | −8.8—−3.1% | −65—−36.6% | −89−1162%−65.9% | 8.4−91.3%7.0% | 96−46.6%79.0% | 180+100%89.1% | 90+31.5%87.0% | 69+320%90.7% | 16—70.7% | |
| Total liabilities and equity | 200−29.8%100% | 286+60.2%100% | 178+31.5%100% | 136+13.3%100% | 120−1.9%100% | 122−39.7%100% | 202+95.4%100% | 104+37.1%100% | 76+228%100% | 23—100% | |
| Shares outstanding | 48+14.5%— | 42+30.0%— | 32+40.5%— | 23+3.0%— | 22+1.3%— | 22+5.4%— | 21+29.7%— | 16+17.9%— | 14+496%— | 2.3—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.3−6.7%0.3% | 0.3−59.0%0.4% | 0.8−13.2%1.0% | 0.9+11.2%1.4% | 0.8+99.8%1.7% | 0.4r0.4+38.7%3.5% | 0.3−25.0%1667% | 0.4+100%35.5% | 0.20.0%2.5% | 0.2—1.1% | |
| Share-based compensation | 12−8.8%10.9% | 13+40.3%14.5% | 9.3−11.7%11.3% | 11−54.2%16.4% | 23−17.5%48.1% | 28−6.5%238% | 30−2.2%166483% | 31+386%2716% | 6.3+220%77.2% | 2.0—11.2% | |
| Cash from operating activities | −162—−148% | −97—−107% | −76—−92.3% | −88—−136% | −85—−177% | −106—−897% | −71—−394539% | −37—−3310% | −9.6r−9.6−328%−117% | 4.2—23.9% | |
| Capital expenditure | −0.3—−0.3% | −0.3—−0.3% | −0.2—−0.2% | −0.3—−0.4% | −0.8—−1.6% | −1.2—−10.3% | −0.3—−1806% | −0.6—−49.6% | −0.3—−3.3% | −0.7—−4.0% | |
| Cash from investing activities | 62—56.1% | −21—−22.8% | −1.0−190%−1.2% | 1.1−73.9%1.6% | 4.1−95.6%8.5% | 93—790% | −146−513%−808850% | 35—3128% | −36r−36—−445% | −0.7r−0.8—−4.1% | |
| Debt issued | 0−100%0.0% | 24—27.1% | 0−100%0.0% | 96—149% | 0—0.0% | — | — | — | — | — | |
| Shares issued | 40−73.7%36.3% | 151+124%167% | 67—81.4% | 0—0.0% | 0−100%0.0% | 16−90.2%134% | 162+152%898122% | 64+5.6%5695% | 61—746% | — | |
| Cash from financing activities | 40−79.5%36.4% | 195+66.4%215% | 117+20.4%141% | 97+34.3%151% | 72+338%151% | 17−90.0%140% | 165+149%918056% | 66+7.9%5888% | 62—755% | −0.0—−0.1% | |
| Change in cash | −61−179%−55.5% | 77+95.0%85.4% | 40+272%47.9% | 11—16.5% | −8.5−319%−17.7% | 3.9—32.9% | −51−180%−285333% | 64+309%5707% | 16r16+355%193% | 3.5r3.4—19.7% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 250+159%100% | 89+224%100% | 72+199%100% | 51+152%100% | 38*+54.0%100% | 27+9.0%100% | 24+10.8%100% | 20+7.8%100% | 25+4.4%100% | 25—100% | 22—100% | 19—100% | 24—100% | |
| Cost of revenue | 22+84.9%8.6% | 7.5+129%8.4% | 6.6+85.1%9.1% | 4.1+77.6%8.1% | 3.3*+33.1%8.7% | 3.3+33.6%11.9% | 3.6+59.3%14.7% | 2.3+34.8%11.5% | 2.5*+8.1%10.1% | 2.5—9.7% | 2.2—10.2% | 1.7—9.2% | 2.3*—9.7% | |
| Gross profit | 229+169%91.4% | 81+237%91.6% | 66+219%90.9% | 47+161%91.9% | 35*+56.4%91.3% | 24+6.4%88.1% | 21+5.3%85.3% | 18+5.1%88.5% | 22+4.0%89.9% | 23—90.3% | 20—89.8% | 17—90.8% | 21—90.3% | |
| Research and development | 73+8.2%29.3% | 26+85.4%29.2% | 17−8.3%23.9% | 16−21.5%30.6% | 14*−3.9%37.8% | 14+23.4%51.0% | 19+22.8%78.1% | 20+28.2%98.1% | 15*+31.8%60.6% | 11—45.1% | 15—70.5% | 15—82.5% | 11*—48.0% | |
| Selling, general and administrative | 186+23.8%74.5% | 47+25.6%53.0% | 48+12.1%66.9% | 51+47.2%101% | 39*+12.9%104% | 38+29.9%137% | 43+43.7%178% | 35+28.1%173% | 35*+42.0%142% | 29—115% | 30—138% | 27—145% | 25*—104% | |
| Operating income | −31—−12.4% | 8.3—9.4% | 0.1—0.2% | −20—−39.8% | −19*—−50.5% | −27—−99.7% | −41—−171% | −37—−182% | −28*—−113% | −18—−69.6% | −26—−118% | −26—−137% | −15*—−62.1% | |
| Interest and finance income | 3.5−56.0%1.4% | 0.7−42.1%0.8% | 0.9−43.6%1.3% | 0.9−57.8%1.8% | 0.9*−67.7%2.4% | 1.2−57.3%4.3% | 1.7+9.3%6.9% | 2.2+22.6%10.9% | 2.8*+287%11.4% | 2.8—10.9% | 1.5r1.7—7.0% | 1.8—9.6% | 0.7*—3.1% | |
| Other non-operating income (expense) | −0.7—−0.3% | −0.1—−0.1% | −0.3—−0.5% | −0.3—−0.6% | −0.0*—−0.0% | −0.2—−0.7% | −0.4−317%−1.6% | −0.1—−0.4% | −0.1*−108%−0.3% | −0.2—−0.6% | 0.2r−0.0—0.8% | −0.2—−1.0% | 0.8*—3.5% | |
| Income before tax | −64—−25.6% | −0.4—−0.5% | −8.7—−12.0% | −28—−55.6% | −27*—−70.4% | −34—−125% | −49—−202% | −43—−215% | −35*—−142% | −24—−93.6% | −33—−153% | −32—−172% | −22*—−94.2% | |
| Income tax | 1.6−46.8%0.6% | 1.0—1.1% | 5.6+455%7.8% | −4.8−1317%−9.4% | −0.3*−110%−0.7% | −1.1−1258%−3.8% | 1.0+2571%4.2% | 0.4+626%1.9% | 2.6*−31.3%10.8% | 0.1—0.4% | 0.0—0.2% | 0.1—0.3% | 3.9*—16.4% | |
| Net income attributable to shareholders | −66—−26.3% | −1.5—−1.6% | −14—−19.8% | −24—−46.3% | −26*—−69.7% | −33—−121% | −50—−206% | −44—−216% | −38—−153% | −24—−93.9% | −33—−153% | −32—−172% | −26—−111% | |
| Earnings per share, basic | — | -0.03—— | -0.28—— | -0.47—— | — | -0.69—— | -1.05—— | -0.92—— | -0.80—— | -0.51r-0.55—— | -0.82r-0.91—— | -0.87r-0.97—— | -0.72—— | |
| Shares, weighted average (basic) | 51+5.2%— | 51+5.2%— | 50+5.5%— | 50+5.8%— | — | 48+2.7%— | 48+17.9%— | 47+28.0%— | 47+30.1%— | 47r43—— | 41r37—— | 37r33—— | 36—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 86—31.5% | 86−5.0%31.5% | 79−14.8%31.3% | 110+5.7%43.3% | 111−35.6%55.2% | 90−27.9%48.7% | 93−57.8%44.5% | 104−20.9%42.0% | 172+81.0%60.2% | 125—41.4% | 220—78.0% | 131—65.5% | 95—53.3% | |
| Short-term investments | 6.4—2.3% | 6.4−90.0%2.3% | 30−63.7%11.9% | 40−64.5%15.7% | 49−55.4%24.6% | 64−58.6%34.5% | 83+59.0%39.8% | 112+117%45.2% | 111r111+97.1%38.7% | 154—51.0% | 52—18.5% | 52—25.8% | 56r56—31.5% | |
| Receivables | 117—43.1% | 117+495%43.1% | 89+352%35.1% | 55+182%21.8% | 33+62.9%16.5% | 20−13.6%10.6% | 20+12.8%9.4% | 20+38.7%7.9% | 20+31.5%7.1% | 23—7.6% | 17—6.2% | 14—7.1% | 15—8.7% | |
| Inventory | 25—9.3% | 25+202%9.3% | 25+245%9.7% | 21+176%8.2% | 16+78.4%8.2% | 8.3+9.8%4.5% | 7.1−4.2%3.4% | 7.6+4.8%3.1% | 9.2+62.6%3.2% | 7.6—2.5% | 7.4—2.6% | 7.2—3.6% | 5.7—3.2% | |
| Other current assets | 18—6.5% | 18+45.1%6.5% | 13+6.0%5.1% | 20+50.4%7.7% | 15+65.9%7.3% | 12−13.7%6.6% | 12−1.3%5.8% | 13+23.8%5.2% | 8.8−14.0%3.1% | 14—4.7% | 12—4.3% | 10—5.2% | 10—5.8% | |
| Current assets | 252—92.7% | 252+49.5%92.7% | 235+19.6%93.2% | 237+0.1%93.6% | 186−32.6%92.8% | 169−42.9%91.1% | 197−29.4%94.3% | 237+20.5%95.8% | 276+63.2%96.6% | 295—97.7% | 279—99.0% | 197—98.1% | 169—94.9% | |
| Property, plant and equipment | 0.6—0.2% | 0.6−15.4%0.2% | 0.6−13.2%0.2% | 0.6−1.8%0.2% | 0.6−2.7%0.3% | 0.7+14.3%0.4% | 0.7+18.6%0.3% | 0.6+10.8%0.3% | 0.7−4.9%0.2% | 0.6—0.2% | 0.6—0.2% | 0.6—0.3% | 0.7—0.4% | |
| Right-of-use (leased) assets | 2.7—1.0% | 2.7−13.2%1.0% | 2.8+132%1.1% | 2.9+357%1.2% | 3.1+263%1.5% | 3.1+194%1.7% | 1.2−3.2%0.6% | 0.6−55.6%0.3% | 0.8—0.3% | 1.1—0.3% | 1.3—0.4% | 1.4—0.7% | 0r1.7—0.0% | |
| Total assets | 272—100% | 272+46.9%100% | 253+21.0%100% | 254+2.5%100% | 200−29.8%100% | 185−38.7%100% | 209−25.9%100% | 248+23.5%100% | 286+60.2%100% | 302—100% | 282—100% | 201—100% | 178—100% | |
| Accounts payable | 17—6.3% | 17+67.9%6.3% | 15+14.1%6.1% | 17+18.1%6.8% | 12+11.0%6.1% | 10+85.0%5.6% | 14+63.1%6.5% | 15+133%5.9% | 11+67.8%3.8% | 5.6—1.8% | 8.3—3.0% | 6.3—3.1% | 6.5—3.7% | |
| Current liabilities | 74—27.2% | 74+75.2%27.2% | 62+30.2%24.5% | 51+20.6%20.0% | 46+1.0%23.2% | 42+28.8%22.8% | 48+38.9%22.8% | 42+59.5%17.0% | 46+47.2%16.1% | 33—10.9% | 34—12.1% | 26—13.1% | 31—17.5% | |
| Long-term debt | 189—69.6% | 189+55.1%69.6% | 189+54.1%74.7% | 190+55.2%74.7% | 122+0.4%61.0% | 122+0.3%66.0% | 123+25.2%58.7% | 122+25.1%49.3% | 122+23.5%42.6% | 122—40.3% | 98—34.7% | 98—48.7% | 99—55.3% | |
| Lease liabilities (non-current) | 2.2—0.8% | 2.2−18.3%0.8% | 2.4+328%0.9% | 2.5+82733%1.0% | 2.6r2.6+4464%1.3% | 2.7+1161%1.4% | 0.6+29.9%0.3% | 0.0−99.5%0.0% | 0.1—0.0% | 0.2—0.1% | 0.4—0.2% | 0.6—0.3% | 0r0.8—0.0% | |
| Total liabilities | 397—146% | 397+32.2%146% | 385+27.4%152% | 378+28.5%149% | 306+3.9%153% | 300+8.7%162% | 302+20.1%145% | 294+22.2%119% | 295+20.9%103% | 276—91.5% | 252—89.2% | 241—120% | 244—137% | |
| Retained earnings | −999—−367% | −999—−367% | −998—−395% | −983—−388% | −960—−479% | −933—−504% | −900—−431% | −850—−343% | −806—−282% | −769—−255% | −745—−264% | −712—−355% | −679—−381% | |
| Shareholders' equity | −125—−46.1% | −125—−46.1% | −132—−52.4% | −124—−49.0% | −105—−52.6% | −115−552%−62.4% | −93−408%−44.7% | −46—−18.8% | −8.8—−3.1% | 26—8.5% | 30—10.8% | −40—−20.0% | −65—−36.6% | |
| Total liabilities and equity | 272—100% | 272+46.9%100% | 253+21.0%100% | 254+2.5%100% | 200−29.8%100% | 185−38.7%100% | 209−25.9%100% | 248+23.5%100% | 286+60.2%100% | 302—100% | 282—100% | 201—100% | 178—100% | |
| Shares outstanding | 49—— | 49+4.8%— | 49+5.8%— | 49+5.7%— | 48+14.5%— | 47+10.9%— | 46+12.2%— | 46+27.6%— | 42+30.0%— | 42—— | 41—— | 36—— | 32—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.4+2.9%0.1% | 0.10.0%0.1% | 0.10.0%0.1% | 0.1+4.2%0.1% | 0.1*+10.3%0.2% | 0.10.0%0.4% | 0.10.0%0.4% | 0.1−41.5%0.4% | 0.1*−64.2%0.3% | 0.1—0.4% | 0.1—0.5% | 0.1—0.7% | 0.2*—0.8% | |
| Share-based compensation | 19+59.4%7.7% | 6.2+106%7.0% | 5.3+95.1%7.4% | 4.6+50.8%9.1% | 3.1*−5.2%8.3% | 3.0−13.2%11.0% | 2.7−23.2%11.3% | 3.1+11.4%15.2% | 3.3*+26.5%13.4% | 3.5—13.8% | 3.6—16.3% | 2.8—14.7% | 2.6*—11.1% | |
| Cash from operating activities | −132—−52.7% | −15*—−17.1% | −33*—−45.6% | −45—−88.9% | −38*—−101% | −42*—−154% | −40*—−164% | −42—−207% | −14*—−55.4% | −28*—−110% | −24*—−109% | −32—−169% | −13*—−55.2% | |
| Capital expenditure | −0.2—−0.1% | −0.1*—−0.1% | −0.1*—−0.1% | −0.1—−0.1% | −0.0*—−0.0% | −0.1*—−0.3% | −0.1*—−0.6% | −0.0—−0.2% | −0.1*—−0.5% | −0.1*—−0.4% | −0.1*—−0.4% | 0—0.0% | −0.1*—−0.2% | |
| Cash from investing activities | 29−69.8%11.4% | 20*−36.8%22.3% | 1.7*−94.1%2.3% | −21—−40.6% | 28*−54.3%73.3% | 31*—114% | 28*+137%117% | −26−292%−128% | 61*—247% | −107*—−424% | 12*—54.9% | 14—72.0% | −11*—−48.2% | |
| Debt issued | 65—26.1% | 0*—0.0% | 0*—0.0% | 65—128% | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | — | — | — | 0*—0.0% | |
| Shares issued | — | — | — | 0−100%0.0% | 32*—84.1% | 8.0*−46.9%29.0% | −0.0*−100%−0.0% | 0.0−100.0%0.0% | 0*—0.0% | 15*—59.5% | 82*—373% | 55—291% | 0*—0.0% | |
| Cash from financing activities | 99+1039%39.5% | 1.8*−78.5%2.0% | 0.5*+68.9%0.7% | 65+191676%128% | 31*+44007%82.8% | 8.3*−79.1%30.1% | 0.3*−99.7%1.2% | 0.0−99.9%0.2% | 0.1*+77.5%0.3% | 40*—157% | 100*—459% | 55—291% | 0.0*—0.2% | |
| Change in cash | −4.5—−1.8% | 6.4*—7.2% | −31*—−42.6% | −0.8—−1.6% | 21*−56.0%54.7% | −2.6*—−9.5% | −11*−113%−45.9% | −68−286%−336% | 47*—192% | −95*—−376% | 89*—405% | 36—194% | −24*—−103% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What UroGen Pharma Ltd. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Jelmyto$94 M86%+4.0%
- Zusduri$16 M14%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where UroGen Pharma Ltd. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at UroGen Pharma Ltd.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Elizabeth A. Barrett | $4.3 M | $11.8 M | $1.2 M | $264 |
| 2024Elizabeth A. Barrett | $4.1 M | $1.9 M | $1.2 M | $120 |
| 2023Elizabeth A. Barrett | $4.6 M | $6.3 M | $1.4 M | $169 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at UroGen Pharma Ltd.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 6 · Material agreement 3 · New debt 2 · Unregistered share sale 1 · Shareholder rights changed 1 · Shareholder vote 3 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder rights changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| New debt | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 4, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2023 | $120 M | Private placement after listing | $50 to $250 million | 8 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by UroGen Pharma Ltd.#
$120 K spent on lobbying the US Congress and federal agencies in 2025.
Lobbying firms hired in 2025
BGR Government Affairs $120 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $90 K | — | 3 |
| 2025 | $120 K | — | 4 |
| 2024 | $90 K | — | 4 |
| 2023 | $120 K | — | 4 |
| 2022 | $220 K | — | 5 |
| 2021 | $160 K | — | 4 |
| 2020 | $160 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “UroGen Pharma, Inc.” and “UroGen Pharma Ltd.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at UroGen Pharma Ltd.#
1 labor condition applications certified in fiscal 2022 for 1 positions, at a median wage of $115 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Manager, Data ManagementClinical Data Managers | 1 | $115 K |
Where: Princeton, NJ 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as UroGen Pharma, Inc.
FDA drug approvals: UroGen Pharma Ltd.#
2 approved applications held; 1 approvals and 0 new uses in 2025.
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (UROGEN PHARMA), so they follow acquisitions
Discuss UroGen Pharma Ltd.#
3 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 4 November 2026automatic update · Nov 4, 2026
UroGen Pharma Ltd. announced results on 4 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $89 million (up 224% from a year earlier) and a net loss of $1 million.
- Insider trading in October 2026automatic update · Oct 31, 2026
Directors and officers of UroGen Pharma Ltd. reported open-market trades for October 2026 (SEC Forms 4 and 5): 1 insider sold shares worth about $80,791 in 1 trade. Awards, option exercises and shares withheld for tax are not counted.
- Mutual funds: 107 funds hold $211 millionautomatic update · Jul 31, 2026
107 mutual funds in 1 country hold shares of UroGen Pharma Ltd. worth $211 million, about 12.0% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 68 funds added shares and 24 sold; on balance they bought $26 million. Share splits are not counted as trading.
How UroGen Pharma Ltd. compares in Biotechnology
- Market cap$1.8 B · higher than 77% of 726
- Revenue$110 M · higher than 70% of 647
- Net margin-139.8% · higher than 37% of 408
- Revenue growth21.4% · higher than 63% of 438
- Price / sales16.3× · lower than 35% of 339
- FCF yield-9.1% · higher than 59% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| UroGen Pharma Ltd.🇺🇸 | $1.8 B | — | -139.8% | +21.4% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- PolyNovo Limited$1.8 B
- Hemab Therapeutics Holdings, Inc.$1.8 B
- Novavax, Inc.$1.8 B
- Porton Pharma Solutions Ltd.$1.8 B
- Xeris Pharmaceuticals$1.8 B
- Maze Therapeutics, Inc.$1.7 B
Sources and freshness
- Market cap:
- Oct 15, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at UroGen Pharma Ltd.? Verify and update this profile — free
Show UroGen Pharma Ltd.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.